Many of us are mindful about eating nutritious foods, but did you know that pairing certain foods together can actually boost the body’s ability to absorb their nutrients and amplify their health benefits?
Blog
-
New antibody drug conjugates can transform early HER2-positive breast cancer treatment
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents-antibody-drug conjugates (ADCs)-can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.
The results from the phase III DESTINY-Breast05 and DESTINY-Breast11 trials, presented in a Presidential Symposium, mark a paradigm shift in breast cancer treatment, positioning ADCs not only as powerful therapeutic agents when the disease has already progressed but also as potential new standards of care in patients with early disease.
There is a particular need for therapies to ensure patients with HER2-positive early breast cancer achieve pathological complete response following neoadjuvant therapies-i.e., delivered before surgery-, and a high unmet need to treat residual disease in those who do not, to prevent the development of metastasis.”
Dr. Evandro de Azambuja from the Jules Bordet Institute, Brussels, Belgium
Currently, trastuzumab emtansine (T-DM1) is the only ADC approved for patients with HER2-positive early breast cancer who show residual invasive disease after neoadjuvant therapy and are at a high risk of recurrence. In the DESTINY-Breast05, Trastuzumab deruxtecan (T-DXd), a new-generation ADC delivering a topoisomerase I inhibitor, showed to improve invasive disease-free survival and disease-free survival by 53% compared with T-DM1 (for both: hazard ratio [HR] 0.47; 95% confidence interval [CI] 0.34–0.66; p<0.0001). Also, T-DXd confirmed its high brain activity, demonstrating a clinically meaningful improvement in brain metastasis-free interval over T-DM1 (HR 0.64; 95% CI 0.35–1.17).
“The generally manageable safety profile and the superior efficacy data suggest that T-DXd should replace T-DM1 as the new standard of care for patients with HER2-positive, residual invasive breast cancer after neoadjuvant therapy,” notes de Azambuja.
The use of T-DXd also showed impressive findings earlier in the treatment pathway- before surgery- as reported in the DESTINY-Breast11 trial where 927 untreated patients with high-risk HER2-positive early breast cancer received either the ADC followed by standard HER2-targeted therapy (THP) or the conventional anthracycline-based regimen (ddAC-THP). The cycles of T-DXd, sequenced with THP, led to a significant increase in the rate of pathological complete response at surgery (67.3% versus 56.3%; p=0.003). “The T-DXd regimen has also the added advantage of an improved safety profile compared with the anthracycline-containing regimen,” comments de Azambuja noting the relevant reduction in cardiac toxicities which was observed with the ADC compared with the conventional treatment.
“In conjunction, these two studies establish T-DXd as a critical treatment option for early-stage HER2-positive breast cancer, ultimately providing a new tool for treatment tailoring for what was once considered the most aggressive subtype of breast cancer, and which today represents the one with the highest chance of cure,” highlights Dr Paolo Tarantino from the Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
After having reshaped the treatment of multiple types of metastatic cancers over the last few years, novel ADCs such as T-DXd are now “raising the bar” in the curative setting due to innovations in their design and mechanism of action. However, their use presents new challenges that need to be addressed. “For instance,
toxicity profiles must be carefully defined and substantial effort to prevent permanent or fatal toxicities is required. Dosing, duration and sequencing of ADCs must also be optimised to achieve maximal efficacy with the least side-effects, and equally critical is the identification of predictive biomarkers that may allow better tailoring of ADC therapy and minimise overtreatment,” clarifies Tarantino.
The presentation of the DESTINY-Breast05 and DESTINY-Breast11 trials results at the ESMO Congress 2025 cements the event’s role as a catalyst for global oncology progress. With ADCs now demonstrating superiority in both pre- and post-surgical settings, the oncology community stands at the threshold of a new chapter-one defined by smarter targeting, earlier intervention and deeper biological understanding.
“Besides the immediate practical impact, in fact, data presented today are expected to have a broader impact on the future of ADC research, marking the formal entrance of the new generation of drugs in the curative arena. This is a therapeutic strategy with tremendous potential, which we are only just starting to unleash, promising to reduce rates of recurrence and improve survival across multiple cancers in the years to come,” concludes Tarantino.
Source:
European Society for Medical Oncology
Continue Reading
-
Egypt’s Pyramids claim CAF Super Cup with 1-0 win over Morocco’s Berkane-Xinhua
CAIRO, Oct. 18 (Xinhua) — Egypt’s Pyramids Football Club captured its maiden CAF Super Cup title on Saturday, after edging Morocco’s Renaissance Berkane 1-0 at Cairo’s 30 June Stadium.
The breakthrough came in the 75th minute when Congolese…
Continue Reading
-
PlayStation’s early Black Friday offers: Gotham Knights, Suicide Squad and EA Sports PGA Tour now for $7 each
With Black Friday and Cyber Monday right around the corner, Sony has jumped early on the deals bandwagon. According to Comicbook.com, the company is offering three major PS5 games for just $7 each on the PlayStation Store.
Reportedly, this is a…
Continue Reading
-
What Do Surging Innodata Shares Signal After Recent Nasdaq 100 Inclusion in 2025?
If you’re eyeing Innodata stock and wondering whether it deserves a spot in your portfolio, you’re not alone. This is a company that’s made headlines for its meteoric rise. In just the past year, Innodata shares have soared an astonishing 322.6%, and the gains grow even more jaw-dropping when looking further back: over 2,000% in three years and nearly 2,900% across the past five. While the last week saw a minor dip of -4.6%, the stock was up 18.7% in the last month and is already up over 100% for 2024 so far. Clearly, there’s serious excitement (and some volatility) surrounding Innodata among investors and traders.
Behind some of these moves are broader market trends and investor enthusiasm for companies driving digital transformation, a space where Innodata has steadily carved out a recognized position. The impressive long-term rally suggests there’s been a major shift in how the market views Innodata’s growth prospects and risk, from an under-the-radar play to a company many now see as a winner in AI-driven data services.
But has the stock’s explosive run made it expensive, or is there still value hiding under the hood? According to our valuation ‘scorecard,’ Innodata is currently considered undervalued in 0 out of 6 widely-followed valuation checks, giving it a score of 0. That might raise some eyebrows after such a strong advance, but a number alone doesn’t tell the whole story.
Let’s walk through the major valuation approaches analysts use for companies like Innodata, and see what each one reveals. And stick around, because at the end, I’ll share a more insightful way to understand if the market is pricing Innodata right.
Innodata scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its future free cash flows and discounting them back to today’s dollars. This approach helps investors understand what a business is fundamentally worth based on the cash it is expected to generate in the years ahead.
For Innodata, the starting point is its latest reported Free Cash Flow (FCF) of $32.58 million. Analyst forecasts see FCF moderating to $26.04 million by the end of 2026, with slight declines projected through 2035. While analysts provide estimates for up to five years, further projections are extrapolated and indicate generally flat to mildly decreasing cash flows into the next decade.
Simply Wall St’s two-stage DCF calculation arrives at an intrinsic value of $16.42 per share. With the company’s current share price well above this estimate, the implied discount suggests Innodata stock is a hefty 383.8% overvalued by this method.
Continue Reading
-
Tracking the Changing Narrative for Sabanci Holding After Key Portfolio and Valuation Updates
Haci Ömer Sabanci Holding stock has seen its estimated fair value rise slightly, up from TRY 143.52 to TRY 146.10, even as growth projections have shifted. According to analyst commentary, this modest uptick in the price target reflects the company’s ability to navigate industry conditions and adapt to changing business dynamics. This is despite some adjustments to revenue expectations and discount rates. Stay tuned to discover how investors and analysts are tracking this evolving story and how you can follow ongoing updates to the narrative.
Analyst perspectives on Haci Ömer Sabanci Holding remain largely constructive, with commentary centering on the company’s recent ability to manage industry shifts and deliver operational consistency. While explicit references to this specific company are limited in the current research inputs, the available analyst outlooks provide insights into the types of factors that have influenced street expectations around valuation and future growth.
🐂 Bullish Takeaways
-
Analysts have generally cited strong execution and a focus on cost reductions as key reasons for the resilience seen in adjusted price targets, despite broader industry challenges.
-
The ability to sustain higher gross margins and exhibit ongoing adaptability is being rewarded with modest price target increases. This highlights confidence in management’s operational discipline.
-
Market participants appear to appreciate continued vigilance in navigating complex business conditions, which contributes to the incremental rise in fair value estimates for the stock.
🐻 Bearish Takeaways
-
Some caution remains, with neutral ratings indicating that while execution is solid, upside may already be reflected in the current valuation.
-
Adjustments to revenue expectations and discount rates remain a key reservation as analysts weigh potential near-term risks to growth momentum.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
IBSE:SAHOL Community Fair Values as at Oct 2025 -
Sabanci Holding is considering divesting certain subsidiaries with lower net profit margins and returns on equity. This potential move was highlighted in recent discussions between executives and analysts, according to Reuters.
-
Market observers report that technology retailer Teknosa and food retailer Carrefoursa are among the businesses that may be evaluated for possible divestiture as Sabanci Holding optimizes its portfolio.
-
The company is reportedly reviewing additional subsidiaries to align its business focus and improve overall financial efficiency. This signals a move toward increased strategic selectivity.
Continue Reading
-
-
Nashville 2-5 Miami (Oct 18, 2025) Game Analysis
NASHVILLE, Tenn. — – Lionel Messi scored his second career MLS hat trick, propelling Inter Miami to a 5-2 win over Nashville SC on Saturday night.
Messi leads the MLS in scoring with 29 goals this season. The last time he scored a hat trick was…
Continue Reading
-
Scientists discover a giant “gravity hole” in the Indian Ocean
Earth carries an invisible ocean “water level” called the geoid. If only gravity and rotation shaped the oceans, the surface would match that geoid everywhere. However, south of India, the geoid sinks sharply.
At the center of this sunken…
Continue Reading
-
Poll results: thank you for your suggestions on improving the Phone Finder’s search for foldables
Last week we asked you for your thoughts on how we should reconfigure our Phone Finder tool to make it easier to find foldable phones with the right dimensions. Here’s how the voting went.
The majority of people prefer that only folded…
Continue Reading
-
What the teams said – Sprint day and Qualifying at the 2025 United States Grand Prix
Mercedes
Russell ran wide on the outside of Turn 1 and managed to avoid the melee that way, which helped his rise to second on the first lap. After the initial Safety Car came in, he managed to stick within DRS range of Verstappen and made one…
Continue Reading
